Journey Medical Co. (NASDAQ:DERM) Short Interest Up 20.5% in February

Journey Medical Co. (NASDAQ:DERM - Get Free Report) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 113,400 shares, a growth of 20.5% from the February 13th total of 94,100 shares. Approximately 1.3% of the company's shares are short sold. Based on an average daily volume of 69,600 shares, the short-interest ratio is currently 1.6 days.

Insider Activity

In other news, CEO Claude Maraoui sold 14,905 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now owns 2,052,418 shares of the company's stock, valued at approximately $10,282,614.18. This represents a 0.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 105,831 shares of company stock valued at $536,622. Corporate insiders own 13.16% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers raised its holdings in Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock worth $54,000 after purchasing an additional 2,478 shares in the last quarter. PVG Asset Management Corp grew its position in shares of Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after buying an additional 9,005 shares during the period. Nwam LLC purchased a new stake in shares of Journey Medical in the 3rd quarter worth about $59,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Journey Medical in the 3rd quarter worth about $66,000. Finally, Geode Capital Management LLC grew its position in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock worth $613,000 after buying an additional 12,882 shares during the period. 7.25% of the stock is currently owned by institutional investors.

Remove Ads

Journey Medical Trading Up 3.1 %

NASDAQ:DERM traded up $0.17 during midday trading on Friday, reaching $5.74. 50,615 shares of the stock traded hands, compared to its average volume of 89,783. The company has a fifty day moving average of $4.85 and a 200 day moving average of $5.12. Journey Medical has a 12 month low of $2.85 and a 12 month high of $6.89. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. The stock has a market capitalization of $119.91 million, a P/E ratio of -6.11 and a beta of 0.97.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.